Rakovina Therapeutics Partners with Boston-based Celvion Therapeutics to Leverage AI and Real-World Clinical Data for Precision Cancer Drug Development

Written by

in

Collaboration to identify optimal combination therapies, predictive biomarkers and patient populations for Rakovina’s ATR inhibitor program

Collaboration to identify optimal combination therapies, predictive biomarkers and patient populations for Rakovina’s ATR inhibitor program

Originally published via Source Article.